Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: Clin Immunol. 2016 Jan 28;164:85–94. doi: 10.1016/j.clim.2016.01.015

Figure 7. Serum IgG ANA levels are decreased following treatment with BAFFR-Fc and anti-CXCL13/BAFFR-Fc.

Figure 7

Hep2 staining was performed using serum from (A) I.C. (n = 4) (B) BAFFR-Fc (n = 4) and (C) Anti-CXCL13/BAFFR-Fc (n = 4) treated mice. Representative staining from each treatment group is shown. Original magnification is 200X. (D) ELISAs were performed to quantify ANA titers in sera from I.C. (n = 10), BAFFR-Fc (n = 9), and anti-CXCL13/BAFF (n = 9) treated animals. I.C. = isotype control. Significance was determined using Mann-Whitney test. Mean and SEM are shown (**, p < 0.01, ***, p < 0.001).